Upload.pdf 891,99KB
1000 Titel
  • Allergen Immunotherapy (AIT) in children: a vulnerable population with its own rights and legislation - summary of EMA-initiated multi-stakeholder meeting on Allergen Immunotherapy (AIT) for children, held at Paul-Ehrlich-Institut, Langen, Germany, 16.1.2019
1000 Autor/in
  1. Mahler, Vera |
  2. Mentzer, Dirk |
  3. Bonertz, Andreas |
  4. Muraro, Antonella |
  5. Eigenmann, Philippe |
  6. Bousquet, Jean |
  7. Halken, Susanne |
  8. Pfaar, Oliver |
  9. Jutel, Marek |
  10. Wahn, Ulrich |
  11. Vieths, Stefan |
  12. Kaul, Susanne |
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-06-29
1000 Erschienen in
1000 Quellenangabe
  • 10:28
1000 FRL-Sammlung
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • |
  • |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Concerning development of medicinal products, children belong to a so-called “special population” for which additional legislation applies: Regulation (EC) No 1901/2006 on medicinal products for paediatric use sets up a system of requirements, rewards and incentives to ensure that medicinal products are researched, developed and authorized to meet the therapeutic needs of children. Allergen Immunotherapy (AIT) is believed to contain a strong potential for immunomodulatory effects inducing sustained clinical efficacy after cessation of treatment (disease modifying effect) and thereby may prevent the progression of the atopic march towards asthma manifestation. However, to this day only few data on long-term effects in general exist and even fewer in children. These are predominantly data from open studies, which are strongly influenced in their validity by the known placebo effect of AIT. Furthermore, there are no studies allowing for the conclusion that efficacy in adults are mirrored by a similar efficacy in children and thus, up to now, it is not possible to extrapolate data from adults to children. The Paediatric Committee (PDCO)—European Medicines Agency’s (EMA) scientific committee responsible for activities on medicines for children—initiated a Multi-Stakeholder Meeting on AIT for Children held at the Paul-Ehrlich-Institut in Langen, Germany, to provide a platform for discussion and exchange of thoughts to this topic between allergy experts from academia, regulators and AIT-manufacturers. The consented meeting minutes, conclusions and participants are presented.
1000 Sacherschließung
lokal European Medicines Agency (EMA)
gnd 4001257-8 Allergie
lokal Paediatric Investigation Plan (PIP)
lokal Allergen Immunotherapy (AIT)
lokal Children
lokal Therapy Allergen Ordinance (TAO)
lokal Paediatric Committee (PDCO)
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
1000 Label
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6432716.rdf
1000 Erstellt am 2022-03-30T14:21:59.865+0200
1000 Erstellt von 323
1000 beschreibt frl:6432716
1000 Bearbeitet von 317
1000 Zuletzt bearbeitet Fri Apr 29 08:03:11 CEST 2022
1000 Objekt bearb. Fri Apr 29 08:03:00 CEST 2022
1000 Vgl. frl:6432716
1000 Oai Id
  1. |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source